glp 1 agonists and sglt2 inhibitors combination Updated evidence on cardiovascular renal effects of GLP-1 receptor and therapy with and finerenone: a narrative review and perspectives | Cardiovascular Diabetology SGLT2 inhibitors vs GLP-1 receptor

Cardiovascular risk Research trials (such as EXAMINE, SAVOR-TIMI-53, TECOS, and CARMELINA) have shown that certain DPP-4 inhibitors do not adversely impact the heart and are cardiovascularly safe [7], [14]

They were assigned 10 or 15 mg of tirzepatide or placebo for 52 weeks

2015A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

This may be due to altered -cell function in diabetic patients, which impairs the efficacy of GLP-1(936)

Peptide agonists typically stabilize multiple receptor conformations, leading to complex signaling cascades involving G-protein activation and -arrestin recruitment

King A, Miller EM